Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Study Investigating the Potential Predictive Value of Neutrophil-to-Lymphocyte Ratio (NLR) and Timing of PD1 Inhibition with Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Ramucirumab plus Docetaxel (RD)

Trial Profile

A Retrospective Study Investigating the Potential Predictive Value of Neutrophil-to-Lymphocyte Ratio (NLR) and Timing of PD1 Inhibition with Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Ramucirumab plus Docetaxel (RD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 26 Sep 2018 Results from a cohort of patients who received ramucirumab+docetaxel as third line treatment presented at the 19th World Conference on Lung Cancer
    • 26 Sep 2018 Results describing baseline characteristics, treatment patterns, and clinical outcomes among RDP patients subsequently treated with ram+doc in the United States presented at the 19th World Conference on Lung Cancer
    • 26 Sep 2018 Results (n=62) presented at the 19th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top